[Effects of short-term application of recombinant human growth hormone on urea production rate in patients in the early postoperative phase].

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To determine the effect of short-term recombinant human growth hormone (rhGH) administration on urea production rate (UPR), N balance and aminograms.

Who Took Part

According to the abstract, 20 patients were involved.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

20 adult patients after major abdominal surgery.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

Intensive care unit of a University Hospital.

The serum levels of hGH, insulin-like growth factor-1 (IGF-1), ACTH and cortisol were measured as well as the amino acids in plasma.

The degree of catabolism was calculated according to Woolfson's formula, which is based on the UPR, and by calculation of the cumulative N balance.

What Was Measured

PubMed files the paper under topics including Abdomen, Adrenocorticotropic Hormone, Growth Hormone, Hydrocortisone, Insulin-Like Growth Factor I, Nitrogen and Postoperative Complications.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1993 (Infusionstherapie und Transfusionsmedizin), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.